No insider purchase over the last 90 days. The latest, by Fatjo, S.L., was filed 13 Jun 2025.
Analysts rate Grifols, S.A. Buy (bullish), based on 12 analysts. Average price target: €14.76.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 31 declarations
A purchase of EUR 7,741,910, filed on June 11, 2025 by Fatjo, S.L., classed Consejero Otros Externos, dominates the record for Grifols, S.A., a Spanish health care company listed in Madrid (market capitalisation of EUR 6.5 billion, 31.2% held by insiders). Next come Tomas Daga Gelabert, EUR 979,015 on September 17, 2021 then, under the spelling Tomás Dagá Gelabert, EUR 660,000 on March 6, 2024. On that last day and the next, 3 filers bought for EUR 1,160,103.
In all, 15 purchases worth EUR 10,937,617 (median EUR 86,480), 2 sales worth EUR 2,341,845 and 14 filings of another kind, or 88% purchases among open-market trades. One sale carries nearly all of it: EUR 2,330,460 for Victor Grifols Roura, Consejero Dominical, on June 15, 2021. Raimon Grifols Roura, vice chairman, has 6 filings (3 purchases); Jose Ignacio Abia Buenache, Consejero Delegado, 3 purchases.
The 31 filings from 16 filers run from May 13, 2021 to September 11, 2026, with a peak of 9 in 2024. The 3 of the last twelve months are neither purchases nor sales. The publication delay is a median of 3 days. For 15 purchases a 90-day result is stored: a median of minus 2.7%, with 47% of results positive. These are recorded past results, not a forecast.
Headquarters: Sant Cugat del Vallès, Spain · Founded: 1909 · 23,234 employees (2021) · Wikipedia article
Source: Wikidata (CC0).